Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.9K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.9K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.8K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK.

HIV medicine·2019
Same author

A Good Book on Massage.

The Hospital·2018
Same author

The efficiency of complement activation in MHC-linked diseases.

Immunology today·2014
Same author

386 computer: a solution to 'computer lag' in medical practice.

Canadian family physician Medecin de famille canadien·2011
Same author

Agenda and infoselect: Personal information managers for physician problem solving.

Canadian family physician Medecin de famille canadien·2011
Same author

Radio-oleic-acid and Radiotriolein Tests in Differential Diagnosis of Steatorrhoea.

British medical journal·2010

Related Experiment Video

Updated: Apr 15, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.6K

Properdin factor D: effects on thrombin-induced platelet aggregation.

A E Davis, D M Kenney

    The Journal of Clinical Investigation
    |September 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Factor D inhibits thrombin-induced platelet aggregation by competitively binding to platelet receptors. This occurs at physiological concentrations, suggesting Factor D may act as an in vivo platelet aggregation inhibitor.

    More Related Videos

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    1.3K
    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
    06:59

    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

    Published on: February 27, 2026

    130

    Related Experiment Videos

    Last Updated: Apr 15, 2026

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
    13:08

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

    Published on: September 9, 2012

    19.6K
    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    1.3K
    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
    06:59

    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

    Published on: February 27, 2026

    130

    Area of Science:

    • Biochemistry
    • Hematology
    • Physiology

    Background:

    • Platelet aggregation is crucial for hemostasis.
    • Thrombin is a key mediator of platelet activation and aggregation.
    • The role of Factor D in platelet function is not fully understood.

    Purpose of the Study:

    • To investigate the effect of Factor D on platelet aggregation.
    • To determine the mechanism by which Factor D influences thrombin-induced platelet aggregation.
    • To assess the potential in vivo role of Factor D in regulating platelet activity.

    Main Methods:

    • Platelet aggregation assays using various agonists (thrombin, collagen, arachidonic acid).
    • Experiments with inactivated Factor D and Factor D pre-absorption.
    • Binding studies using radiolabeled Factor D and thrombin on platelet suspensions.
    • Kinetic analysis of thrombin binding in the presence of Factor D.

    Main Results:

    • Factor D significantly inhibited thrombin-induced platelet aggregation.
    • Inhibition was observed even with enzymatically inactive Factor D.
    • Factor D competitively inhibited thrombin binding to platelets, altering the dissociation constant.
    • Factor D binds to platelets in a manner similar to thrombin.

    Conclusions:

    • Factor D acts as a competitive inhibitor of thrombin binding to platelet receptors.
    • The inhibitory effect of Factor D on platelet aggregation is independent of its enzymatic activity.
    • Factor D may play a physiological role in modulating platelet aggregation in vivo.